"10.1371_journal.pone.0063365","plos one","2013-05-28T00:00:00Z","Siân C Piper; John Ferguson; Linda Kay; Lisa C Parker; Ian Sabroe; Matthew A Sleeman; Emmanuel Briend; Donna K Finch","Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, United Kingdom; Department of Infection and Immunity, Faculty of Medicine, University of Sheffield, Sheffield, United Kingdom","Conceived and designed the experiments: SCP JF LK LCP IS MAS EB DKF. Performed the experiments: SCP JF LK LCP. Analyzed the data: SCP JF LK LCP IS EB DKF. Contributed reagents/materials/analysis tools: IS LCP. Wrote the paper: SCP JF LCP IS MAS EB DKF. Final approval: MAS.","The authors have the following interests: All work was funded by MedImmune Ltd, the employer of Siân C Piper, John Ferguson, Matthew A. Sleeman, Emmanuel Briend and Donna K. Finch who may receive AstraZeneca shares as part of their usual renumeration. MedImmune Ltd is currently evaluating antibodies to IL-1RI and IL-18 for use in COPD patients, and has filed associated patents. The HRV14 and HRV1b virus preparations used in this study were generated and purified by Laura Liggins and Melanie Snow within Discovery Enabling Capabilities and Science (DECS) at AstraZeneca R&D, Alderley Park, UK. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","05","Siân C Piper","SCP",8,TRUE,8,4,7,7,TRUE,TRUE,FALSE,0,NA,FALSE
